Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients
WJ Burke, I Gergel, A Bose - Journal of Clinical Psychiatry, 2002 - psychiatrist.com
Background: Escitalopram is the single isomer responsible for the serotonin reuptake inhibition
produced by the racemic antidepressant citalopram. The present randomized, double-…
produced by the racemic antidepressant citalopram. The present randomized, double-…
Escitalopram in the treatment of generalized anxiety disorder: Double‐blind, placebo controlled, flexible‐dose study
JRT Davidson, A Bose, A Korotzer… - Depression and …, 2004 - Wiley Online Library
Escitalopram has been shown in clinical trials to improve anxiety symptoms associated with
depression, panic disorder, and social anxiety disorder. This study was designed to evaluate …
depression, panic disorder, and social anxiety disorder. This study was designed to evaluate …
[HTML][HTML] A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia
…, Y Du, J Zummo, L Corey, A Bose… - The Journal of clinical …, 2015 - psychiatrist.com
Objective: This study evaluated the efficacy, safety, and tolerability of aripiprazole lauroxil, a
novel long-acting injectable atypical antipsychotic, for the treatment of schizophrenia. Method…
novel long-acting injectable atypical antipsychotic, for the treatment of schizophrenia. Method…
Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo …
GM Asnis, A Bose, CP Gommoll, C Chen… - J Clin …, 2013 - psychiatrist.com
Objective: This phase 3, randomized, double-blind, placebo-controlled study evaluated the
efficacy and tolerability of fixed-dose levomilnacipran sustained release (SR) compared with …
efficacy and tolerability of fixed-dose levomilnacipran sustained release (SR) compared with …
A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder
RJ Bielski, A Bose, CC Chang - Annals of Clinical Psychiatry, 2005 - Taylor & Francis
Background. This study compared the efficacy and tolerability of escitalopram, a newer SSRI,
with paroxetine in the treatment of generalized anxiety disorder (GAD). Methods. Patients …
with paroxetine in the treatment of generalized anxiety disorder (GAD). Methods. Patients …
Escitalopram continuation treatment prevents relapse of depressive episodes
MH Rapaport, A Bose, H Zheng - Journal of Clinical Psychiatry, 2004 - psychiatrist.com
Background: Current guidelines for antidepressant use recommend 4 to 6 months of
continuation treatment to prevent relapse of depression following symptom resolution. This study …
continuation treatment to prevent relapse of depression following symptom resolution. This study …
Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials
WK Goodman, A Bose, Q Wang - Journal of Affective Disorders, 2005 - Elsevier
BACKGROUND: Escitalopram 10 mg/day is an effective and well-tolerated antidepressant.
Three randomized controlled trials recently evaluated the safety and efficacy of escitalopram …
Three randomized controlled trials recently evaluated the safety and efficacy of escitalopram …
[HTML][HTML] A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder
A Sambunaris, A Bose, CP Gommoll… - Journal of Clinical …, 2014 - journals.lww.com
Levomilnacipran (1S, 2R-milnacipran) is a potent and selective serotonin and norepinephrine
reuptake inhibitor; an extended-release (ER) formulation allows for once-daily dosing. …
reuptake inhibitor; an extended-release (ER) formulation allows for once-daily dosing. …
Original Research Efficacy and Safety of Levomilnacipran Sustained Release in
SA Montgomery, L Mansuy, A Ruth, A Bose, H Li… - J Clin …, 2013 - psychiatrist.com
Objective: To investigate the efficacy and safety of levomilnacipran sustained release (SR),
an antidepressant candidate in late-stage development, in major depressive disorder (MDD). …
an antidepressant candidate in late-stage development, in major depressive disorder (MDD). …
Escitalopram in the treatment of adolescent depression: a randomized, double-blind, placebo-controlled extension trial
RL Findling, A Robb, A Bose - Journal of child and adolescent …, 2013 - liebertpub.com
Objective: The purpose of this study was to evaluate the extended efficacy, safety, and tolerability
of escitalopram relative to placebo in adolescents with major depressive disorder (MDD…
of escitalopram relative to placebo in adolescents with major depressive disorder (MDD…